Kurt Von Emster is a managing partner at Abingworth, a leading life science investment firm focused on therapeutics. He has been with the firm since 2015.
Von Emster serves or has served on the boards of numerous biotech and pharmaceutical companies, including Tizona Therapeutics, Vera Therapeutics, Trishula Therapeutics, Orbus Therapeutics, SFJ Pharmaceuticals, SutroVax, CymaBay, CRISPR Therapeutics, Kesios Therapeutics, Cytos Biotechnology, Aurinia Pharmaceutical, Somaxon Pharmaceuticals, and Facet Biotech.
Additionally, he was a founding partner of investment advisory firm venBIO LLC (2009 to 2015), a general partner and portfolio manager at MPM Capital (2000 to 2009), and the vice president of portfolio manager at Franklin Templeton Investments (1989 to 2000).
His investing career was launched at Franklin Templeton where he founded and managed several health and biotech funds in the 1990s, each earning 5-star rankings from Mornignstar. By 2000, he was managing over $2 billion in funds for the firm.
Von Emster earned his B.S. in business and economics from the University of California, Santa Barbara.
What is Kurt Von Emster's net worth?
The estimated net worth of Kurt Von Emster is at least $4.31 million as of September 29th, 2023. Mr. Emster owns 90,000 shares of CRISPR Therapeutics stock worth more than $4,309,200 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Emster may own. Learn More about Kurt Von Emster's net worth.
How do I contact Kurt Von Emster?
Has Kurt Von Emster been buying or selling shares of CRISPR Therapeutics?
Kurt Von Emster has not been actively trading shares of CRISPR Therapeutics in the last ninety days. Most recently, Kurt Von Emster sold 72,934 shares of the business's stock in a transaction on Tuesday, December 18th. The shares were sold at an average price of $29.85, for a transaction totalling $2,177,079.90. Learn More on Kurt Von Emster's trading history.
Who are CRISPR Therapeutics' active insiders?
Are insiders buying or selling shares of CRISPR Therapeutics?
In the last year, insiders at the sold shares 14 times. They sold a total of 192,740 shares worth more than $12,514,312.47. The most recent insider tranaction occured on November, 11th when CEO Samarth Kulkarni sold 30,000 shares worth more than $1,668,600.00. Insiders at CRISPR Therapeutics own 4.1% of the company.
Learn More about insider trades at CRISPR Therapeutics. Information on this page was last updated on 11/11/2024.
